End Drug Shortages Act
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The End Drug Shortages Act (S.5368) is a Senate bill from the 118th Congress aimed at addressing the issue of drug shortages in the United States. While the official summary and full text are not available, the bill was referred to the Senate Committee on Health, Education, Labor, and Pensions for further consideration. The bill falls under the health policy area and seeks to implement measures to mitigate or prevent shortages of pharmaceutical drugs, which can impact patient care and public health.
S.5368 is a health-focused legislative proposal intended to reduce drug shortages, but it did not advance beyond committee referral and ultimately failed or expired.
- The bill targets the problem of drug shortages, a significant issue affecting healthcare delivery.
- It was introduced in the Senate and referred to the Committee on Health, Education, Labor, and Pensions.
- The bill did not progress to enactment and is currently classified as failed or expired.
['Patients requiring medications affected by shortages', 'Healthcare providers and hospitals managing drug inventories', 'Pharmaceutical manufacturers and distributors involved in supply chain stabilization', 'Public health agencies concerned with drug availability']
['Lack of publicly available full text limits assessment of specific implementation mechanisms and costs', 'Unclear enforcement provisions or authority delegation due to missing bill text', 'Potential challenges in balancing regulatory oversight with pharmaceutical industry operations', 'Uncertainty about funding sources or budgetary impact']
The bill was introduced in the Senate during the 118th Congress and referred to the relevant health committee. It did not advance beyond committee consideration and is now categorized as failed or expired. Drug shortages have been a recurring issue in U.S. healthcare policy, prompting legislative efforts to improve supply chain resilience and drug availability.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Improved drug supply chain management could reduce healthcare disruptions and improve patient outcomes if implemented.', 'Regulatory changes may affect pharmaceutical manufacturing and distribution practices.', 'Potential budgetary implications for federal agencies overseeing drug supply monitoring.']
Transparency is limited due to the absence of the full bill text and official summary, which restricts detailed oversight and public understanding. The bill's failure to advance past committee stage suggests limited legislative momentum. Future proposals addressing drug shortages would benefit from clear, accessible documentation to facilitate comprehensive analysis and stakeholder engagement.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.